Pancreatic cancer is typically diagnosed through a combination of imaging scans, blood tests, and tissue sampling, with a contrast-enhanced CT scan serving as the primary first step. Because the pancreas sits deep in the abdomen and early symptoms are vague, diagnosis often involves multiple rounds of testing to confirm the presence of cancer, rule out other conditions, and determine whether surgery is possible.
CT Scans Are the First-Line Test
When pancreatic cancer is suspected, the standard starting point is a specialized CT scan called a pancreas protocol CT. This isn’t an ordinary CT. It uses intravenous contrast dye and captures images in multiple phases as the dye moves through your blood vessels and pancreas, with very thin image slices (3 mm or less). These phases highlight the pancreas tissue and surrounding blood vessels in ways a standard CT cannot, making it possible to see both the tumor itself and whether it has grown into nearby structures.
The scan typically covers the chest, abdomen, and pelvis to check whether the cancer has spread. This single test often provides enough information to guide the next steps, including whether surgery might be an option.
When CT Isn’t Enough: MRI and Ultrasound
Some pancreatic tumors don’t show up clearly on CT because they have the same density as normal pancreas tissue. When this happens, or when a patient can’t receive CT contrast dye, an abdominal MRI is the next option. MRI is particularly useful for spotting smaller or subtler lesions. If MRI is used instead of CT for the abdomen, a separate chest CT is still needed to check for spread to the lungs.
A specialized imaging technique called MRCP (magnetic resonance cholangiopancreatography) can visualize the pancreatic duct and bile duct without any invasive procedure. It has a sensitivity of about 84% and specificity of 97% for detecting pancreatic cancer, making it a reliable noninvasive alternative to older techniques that required threading a scope into the ducts.
Endoscopic ultrasound (EUS) uses a small ultrasound probe on the end of a flexible scope passed through the mouth and into the stomach. Because the stomach sits right next to the pancreas, this approach produces extremely detailed close-up images. EUS is especially valuable for tumors that are hard to see on CT, for assessing whether the tumor involves nearby veins, and for obtaining tissue samples.
The Role of CA 19-9 Blood Tests
CA 19-9 is a protein that pancreatic cancer cells often release into the bloodstream. Normal levels fall below 35 U/mL. Elevated levels can support a suspected diagnosis and help track how well treatment is working later on, but this test has significant limitations.
CA 19-9 is not sensitive or specific enough to screen for pancreatic cancer on its own. Levels can be elevated by other conditions, including bile duct blockages, liver disease, and other cancers. And roughly 5% to 7% of people are genetically unable to produce CA 19-9 at all, regardless of whether cancer is present. These individuals lack a specific enzyme needed to make the protein, so their levels will read as normal even with advanced disease. For these reasons, CA 19-9 is used alongside imaging and biopsy rather than as a standalone diagnostic tool.
Getting a Tissue Sample
Imaging can strongly suggest pancreatic cancer, but a definitive diagnosis requires examining actual cells under a microscope. The most common way to get those cells is through EUS-guided fine needle aspiration or biopsy (EUS-FNAB). During this procedure, a thin needle is passed through the endoscopic ultrasound probe directly into the pancreatic mass while you’re under sedation.
This technique is highly accurate. For pancreatic tumors, EUS-FNAB has sensitivity rates between 84% and 93%, specificity between 96% and 100%, and overall accuracy above 90%. Even for very small tumors (10 mm or less), the procedure achieves about 82% sensitivity and 95% specificity, though the technical success rate drops somewhat with smaller lesions.
Under the microscope, the most common type of pancreatic cancer (ductal adenocarcinoma, which accounts for roughly 90% of cases) shows a distinctive pattern: gland-like structures surrounded by dense scar-like tissue, often with mucin production. Pathologists look for these specific features to distinguish it from rarer types like neuroendocrine tumors, which require different treatment approaches.
Ruling Out Conditions That Mimic Cancer
One of the trickiest aspects of pancreatic cancer diagnosis is distinguishing it from autoimmune pancreatitis (AIP), a treatable inflammatory condition that can look remarkably similar on imaging. Both can cause a mass in the pancreas, jaundice, and weight loss.
Radiologists use specific imaging patterns to sort patients into likelihood categories. Diffuse enlargement of the entire pancreas strongly suggests AIP, while a distinct low-density mass with a cutoff of the pancreatic duct and shrinkage of the upstream pancreas points toward cancer (this pattern is confirmed as cancer about 92% of the time). Cases that fall in between require additional workup.
A blood test measuring IgG4, an antibody associated with autoimmune conditions, helps clarify ambiguous cases. When IgG4 levels are more than double the upper limit of normal, especially combined with signs of autoimmune disease in other organs, the diagnosis is almost certainly AIP rather than cancer. When blood tests aren’t conclusive, a core biopsy of the pancreas or a short trial of steroid medication (which rapidly improves AIP but not cancer) may be needed to reach a final answer.
How Imaging Determines Surgical Options
Beyond confirming the diagnosis, imaging plays a critical role in determining whether the tumor can be surgically removed, which is currently the only potential cure. The key factor is the tumor’s relationship to four major blood vessels near the pancreas: the portal vein, common hepatic artery, celiac trunk, and superior mesenteric artery.
Tumors fall into three categories based on this assessment:
- Resectable: The tumor has not grown into major blood vessels and can be removed with surgery.
- Borderline resectable: The tumor touches or partially involves a major blood vessel or nearby tissue. Surgery may still be possible, but there’s a higher risk of not removing all cancer cells. Chemotherapy before surgery is often used to improve the chances.
- Locally advanced: The tumor has grown into or around major blood vessels to the point where surgery cannot completely remove it.
This classification directly shapes the treatment plan, which is why the quality of the initial CT scan matters so much. A pancreas protocol CT with proper timing and thin slices gives surgeons the vascular detail they need to make this call accurately.
Tests That Are Not Routinely Recommended
PET-CT, which highlights metabolically active cells throughout the body, is not routinely recommended for diagnosing pancreatic cancer. While it can be useful in specific situations (like clarifying whether a distant spot is a metastasis), it doesn’t add enough to the standard workup to justify routine use.
ERCP, a procedure that threads a scope into the bile and pancreatic ducts, has little diagnostic value beyond what CT or MRI already provides. It’s now reserved mainly for therapeutic purposes, such as placing a stent to relieve a blocked bile duct causing jaundice.
Liquid biopsies, which detect cancer-related DNA fragments in a blood draw, have generated significant interest but remain limited in this context. No liquid biopsy test has been FDA-approved for detecting or screening for pancreatic cancer. The liquid biopsies that do have FDA approval are designed for people who already have a confirmed cancer diagnosis, helping guide treatment decisions rather than making the initial diagnosis.